Acrosyndromes (Raynaud's phenomenon and related disorders)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Suspected primary form
- In this situation, no laboratory test is recommended
Laboratory tests
- Antinuclear antibodies (ANA) (to rule out early connective tissue disease)if neededThe ESVM (Europe, 2017) requests them in every patient with Raynaud's phenomenon [2]; in France, the rare diseases network, the SFMV and the COFER do too, together with capillaroscopy, whereas the Collège de médecine interne does not recommend any tests for a typical presentation [3]. Their absence at baseline is the factor most associated with non-progression to scleroderma at 5 years (European VEDOSS cohort) [4]. A low titre (1/40, for example) does not rule out a primary form [5].
- FBCif neededThe ESVM requests them in every patient with Raynaud's phenomenon, ESR being able to replace CRP (expert opinion) [2]; in France, the rare diseases network, the SFMV and the COFER list them as “±” [3]. A normal CRP does not rule out a connective tissue disease [2].
- CRPif neededThe ESVM requests them in every patient with Raynaud's phenomenon, ESR being able to replace CRP (expert opinion) [2]; in France, the rare diseases network, the SFMV and the COFER list them as “±” [3]. A normal CRP does not rule out a connective tissue disease [2].
Do not order
- Laboratory tests for acrocyanosis, spontaneous finger haematomas or typical bilateral chilblains: the tests are useless [8].
Suspected scleroderma
Laboratory tests
- FBC
- CRP
- Antinuclear antibodies (ANA)
- TSHif neededDepending on the clinical context: the rare diseases network, the SFMV and the COFER list them as “±” without specifying the situation [3].
- rheumatoid factorif neededDepending on the clinical context: the rare diseases network, the SFMV and the COFER list them as “±” without specifying the situation [3].
Urine tests
- Urine dipstick (to look for renal involvement)if needednon-French guidelineThe ESVM (Europe, 2017) considers it useful to detect renal involvement, for example in lupus [2]; a US-UK review lists it among the tests often requested [4]. The tests of the rare diseases network, the SFMV and the COFER do not mention it [3].
Second-line tests if the tests above are abnormal
Laboratory tests
- Anti-Scl70
- Anti-centromere
- Anti-RNP
- Anticardiolipin
- Cryoglobulins
Erythromelalgia: look for a myeloproliferative neoplasm
Laboratory tests
- FBC
- Antinuclear antibodies (ANA) (if signs of rheumatic or autoimmune disease)if neededClinical signs suggesting a rheumatic or autoimmune disease: secondary erythromelalgia can accompany these diseases [10]. Together with the FBC and the search for thyroid dysfunction, antinuclear antibody testing helps distinguish a primary form from a secondary one; erythromelalgia can accompany lupus [8].
- TSH (if signs of hyperthyroidism)if neededClinical signs of hyperthyroidism: erythromelalgia can, more rarely, accompany hyperthyroidism, and the search for thyroid dysfunction is among the tests that distinguish primary from secondary forms [8].
If the FBC is normal: to be repeated regularly
- FBC
Also consider
Sources (14)
- Roquelaure Y, et al. Risk factors for Raynaud's phenomenon in the workforce. Arthritis Care Res (Hoboken). 2012;64:898-904.
- Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon. Vasa. 2017;46(6):413-23.
- Phénomène de Raynaud ou syndrome de Raynaud
- Ramahi A, Hughes M, Khanna D. Practical management of Raynaud’s phenomenon - a primer for practicing physicians. Curr Opin Rheumatol. 2022;34(4):235-44.
- Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun. 2014;48-49:60-5.
- National Health Service (Royaume-Uni). Raynaud’s (page d’information destinée aux patients, dernière révision le 20 juillet 2023), consultée le 30 octobre 2026.
- Pain CE, Constantin T, Toplak N, et al. Raynaud’s syndrome in children: systematic review and development of recommendations for assessment and monitoring (Paediatric Rheumatology European Society, groupe de travail sur la sclérodermie juvénile). Clin Exp Rheumatol. 2016;34 Suppl 100(5):200-6.
- Senet P. Diagnostic des acrosyndromes vasculaires. Ann Dermatol Venereol. 2015;142(8-9):513-8 (formation médicale continue, Société française de dermatologie).
- van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47.
- Miranda S, Le Besnerais M, Langlois V, Benhamou Y, Lévesque H. L'érythromélalgie : approche diagnostique et thérapeutique actuelle. Rev Med Interne. 2017;38(3):176-80.
- Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med. 1989;149(1):105-9.
- Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102(4):466-71.
- Klein-Weigel PF, Volz TS, Richter JG. Erythromelalgia. Vasa. 2018;47(2):91-7.
- Tang Z, Chen Z, Tang B, Jiang H. Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015;10:127.